---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-206455"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:20:02.817042+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q1 revenue $70.9M, up 35% YoY; MRD revenue up 53%; raises FY2026 MRD guidance to $260-270M

## Summary
- Q1 revenue $70.9M (+35% YoY); MRD revenue $67.1M (+53% YoY); clonoSEQ test volume 32,595 (+41%).
- Net loss narrowed to $20.0M from $29.8M; adj. EBITDA loss $2.5M improved from $12.7M loss.
- Raised FY2026 MRD revenue guidance to $260-270M (from $255-265M), implying 22-27% annual growth.
- Recognized $9.0M in MRD pharma regulatory milestone revenue, first U.S. primary endpoint milestone.
- Immune Medicine revenue $3.8M (-57% YoY); cash & equivalents $237.2M.

## SEC filing metadata
- accession: 0001193125-26-206455
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000119312526206455/0001193125-26-206455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000119312526206455/adpt-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-206455
- JSON: https://secwatch.observer/filing/0001193125-26-206455.json
- Plain text: https://secwatch.observer/filing/0001193125-26-206455.txt

## Source-grounded claims
- claim_id: 2315d86724169f954dba5bf5b5e9fe0bcf0f020b
  claim: Adaptive Biotechnologies Corp updated its full year 2026 guidance (raised).
  evidence_excerpt: Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000119312526206455/0001193125-26-206455-index.htm
- claim_id: cbe4a044c641e9b722120794c06a84fafe1dce6c
  claim: Adaptive Biotechnologies Corp reported the quarter ended March 31, 2026 results: revenue $70.9 million, net income $20.0 million.
  evidence_excerpt: First Quarter 2026 Financial Results Revenue was $70.9 million for the quarter ended March 31, 2026, representing a 35% increase from the first quarter in the prior year. Excluding revenue recognized under the Genentech Agreement, which did not generate revenue in the quarter ended March 31, 2026, revenue for the current quarter increased 45% from the first quarter in the prior year. MRD revenue was $67.1 million for the quarter, representing a 53% increase from the first quarter in the prior year. Immune Medicine revenue was $3.8 million for the quarter, representing a 57% decrease from the first quarter in the prior year. Excluding revenue from the Genentech Agreement, Immune Medicine revenue for the quarter ended March 31, 2026 decreased 26% from the first quarter in the prior year. Operating expenses for the first quarter of 2026 were $90.1 million, compared to $82.0 million in the first quarter of the prior year, representing an increase of 10%. Interest and other income, net was
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000119312526206455/0001193125-26-206455-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.